XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation August 31, 2026 · Financial Post Read MoreVisit biznow.biz for more information. Read full story at source